INMB
- INmune Bio, Inc.
()
Overview
Company Summary
INmune Bio, Inc. (INMB) is a clinical-stage biotechnology company focused on developing therapies that aim to harness the body's innate immune system to treat various diseases, including cancer and Alzheimer's disease. The company specializes in the field of immunology, which involves understanding how the immune system functions and utilizing its capabilities to combat diseases.
INmune Bio employs a unique approach to target diseases by specifically addressing components of the innate immune system. This approach involves modulating certain pathways and proteins within the immune system that play critical roles in fighting disease and inflammation. The company's therapies are designed to activate or suppress these specific immune responses, depending on the disease being targeted.
INmune Bio's pipeline of innovative drug candidates includes INB03, a potential treatment for cancer, and XPro1595, a drug candidate aimed at treating neuroinflammation associated with Alzheimer's disease. Both therapies have shown promise in early preclinical and clinical studies.
INB03 is an anti-tumor necrosis factor (TNF) therapeutic that aims to enhance the body's anti-cancer immune response while minimizing toxic side effects often associated with similar immunotherapeutic drugs. This therapy has the potential to enhance the effectiveness of traditional cancer treatments, such as chemotherapy and radiation therapy.
XPro1595, on the other hand, focuses on inhibiting soluble TNF, which is believed to drive chronic inflammation in the brain, contributing to neurodegenerative diseases like Alzheimer's. By targeting this specific component of the immune system, INmune Bio seeks to reduce neuroinflammation and potentially slow or halt the progression of cognitive decline associated with Alzheimer's disease.
Overall, INmune Bio's mission is to develop novel therapies that capitalize on the body's innate immune system to address significant unmet medical needs. By advancing its drug candidates through clinical trials and pursuing regulatory approvals, the company aims to bring innovative treatments to patients who are currently underserved by conventional therapies.